BR112016017764A2 - anticorpo antidengue de amplo espectro - Google Patents

anticorpo antidengue de amplo espectro

Info

Publication number
BR112016017764A2
BR112016017764A2 BR112016017764A BR112016017764A BR112016017764A2 BR 112016017764 A2 BR112016017764 A2 BR 112016017764A2 BR 112016017764 A BR112016017764 A BR 112016017764A BR 112016017764 A BR112016017764 A BR 112016017764A BR 112016017764 A2 BR112016017764 A2 BR 112016017764A2
Authority
BR
Brazil
Prior art keywords
antibody
antibody agents
antidengue
broad spectrum
serotypes
Prior art date
Application number
BR112016017764A
Other languages
English (en)
Portuguese (pt)
Inventor
Tharakaraman Kannan
Sasisekharan Ram
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BR112016017764A2 publication Critical patent/BR112016017764A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016017764A 2014-02-11 2015-02-11 anticorpo antidengue de amplo espectro BR112016017764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (1)

Publication Number Publication Date
BR112016017764A2 true BR112016017764A2 (pt) 2017-10-10

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017764A BR112016017764A2 (pt) 2014-02-11 2015-02-11 anticorpo antidengue de amplo espectro

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG11201606163QA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
SG11201500605TA (en) 2012-08-07 2015-02-27 Massachusetts Inst Technology Anti-dengue virus antibodies and uses thereof
JP6707455B2 (ja) 2014-02-11 2020-06-10 マサチューセッツ インスティテュート オブ テクノロジー 新規フルスペクトル抗デング抗体
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
MX2019007564A (es) 2016-12-23 2019-09-06 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion corriente abajo y formulaciones de anticuerpos estables obtenidas a partir de los mismos.
TWI887899B (zh) 2018-03-15 2025-06-21 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
WO2004039399A1 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2005056600A2 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
BRPI0614265A2 (pt) * 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
BRPI0823197A2 (pt) 2008-10-05 2015-06-23 Univ Leland Stanford Junior Anticorpos contra hepatite c e aplicações dos mesmos
WO2010043977A2 (en) 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
AU2009322185A1 (en) 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
SG173482A1 (en) 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) * 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
SG11201500605TA (en) 2012-08-07 2015-02-27 Massachusetts Inst Technology Anti-dengue virus antibodies and uses thereof
JP6707455B2 (ja) 2014-02-11 2020-06-10 マサチューセッツ インスティテュート オブ テクノロジー 新規フルスペクトル抗デング抗体
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用

Also Published As

Publication number Publication date
CN106413749A (zh) 2017-02-15
US11421018B2 (en) 2022-08-23
AU2015217149A1 (en) 2016-09-08
AU2015217149B2 (en) 2020-09-10
JP2017507131A (ja) 2017-03-16
KR20160119806A (ko) 2016-10-14
SG11201606163QA (en) 2016-08-30
US20150368321A1 (en) 2015-12-24
MX2016009991A (es) 2016-10-07
US20180237504A1 (en) 2018-08-23
US20200207841A1 (en) 2020-07-02
CA2938495A1 (en) 2015-08-20
EP3104888A1 (en) 2016-12-21
US9902764B2 (en) 2018-02-27
JP6707455B2 (ja) 2020-06-10
US10519220B2 (en) 2019-12-31
MX375402B (es) 2025-03-06
SG10201807826XA (en) 2018-10-30
IL246788A0 (en) 2016-08-31
EP3104888A4 (en) 2017-08-09
CN106413749B (zh) 2022-04-05
WO2015123362A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
BR112018067696A2 (pt) membros de ligação à pd-l1
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791270A1 (ru) Модифицированные april-связывающие антитела
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
MX2016002166A (es) Anticuerpos.
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
EA201592203A1 (ru) Способы лечения таупатии

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.